Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Pegfilgrastim (Fulphila) - decreasing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.

Pegfilgrastim (Fulphila) - decreasing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs. Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information

2019 Health Canada - Drug and Health Product Register

2. Human Immunodeficiency Virus (HIV) Infection: Screening

Human Immunodeficiency Virus (HIV) Infection: Screening Final Update Summary: Human Immunodeficiency Virus (HIV) Infection: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Human Immunodeficiency Virus (HIV) Infection: Screening Release Date: June 2019 Recommendation Summary Population Recommendation (...) Grade Adolescents and adults aged 15 to 65 years The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. Pregnant persons The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. To read the recommendation statement in JAMA , select

2019 U.S. Preventive Services Task Force

3. Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis Final Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Summary YouTube embedded video: https://www.youtube-nocookie.com/embed/guahk43RkV4 Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure (...) therapy. ( ) Related Information for Consumers Related Information for Health Professionals Supporting Documents ( ) ( ) Clinical Summary Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice. This summary is intended for use by primary care clinicians. ( ) Current as of: June 2019 Internet Citation: Final Update Summary: Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis . U.S. Preventive

2019 U.S. Preventive Services Task Force

4. Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE.

Chiefs’ inquiry corner: monoclonal antibodies and clostridium difficile infection, outcomes after in-hospital cardiac arrest v out-of-hospital, dermatomyositis and malignancy, malignancy work up in unprovoked VTE. Chiefs’ Inquiry Corner – Clinical Correlations Search Chiefs’ Inquiry Corner June 10, 2019 3 min read Clostridium difficile (C diff) is the most common pathogen implicated in infectious diarrhea among hospitalized patients. Several antimicrobials, chief among them an oral formulation (...) of vancomycin, are utilized to combat and prevent infection in appropriate patients. Monoclonal antibodies specific to cdiff’s binary toxins A and B have also been developed and can be effective in reducing recurrent infection. The MODIFY trials (2017) randomized patients being treated with standard antibiotics for c diff infection to additional infusion of either monoclonal antibody to toxin A (actoxumab), toxin B (bezlotoxumab), or both, compared to placebo controls. (The group receiving actoxumab alone

2019 Clinical Correlations

5. Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015

Neonatal Herpes Simplex Virus Infection Among Medicaid-Enrolled Children: 2009-2015 To examine the incidence, mortality, and health care use related to neonatal herpes simplex virus (HSV) infection.A retrospective longitudinal cohort study using a multistate Medicaid claims database. We identified neonates hospitalized with HSV infection from 2009 to 2015 by using discharge diagnosis codes and managed them for 6 months after discharge. Incidence rates were corrected for the imperfect (...) sensitivity and specificity of thediagnosis codes for identifying HSV infection.Of 2 107 124 births from 2009 to 2015, 900 neonates were identified with HSV infection, with a corrected incidence rate of 4.5 (95% confidence interval [CI]: 4.2-4.8) per 10 000 births. The yearly disease incidence increased by 56%, from 3.4 (95% CI: 2.8-4.2) per 10 000 births (or 1 in 2941 births) in 2009 to 5.3 (95% CI: 4.6-6.1) per 10 000 births (or 1 in 1886 births) in 2015 (P < .001). Of the 900 neonates with HSV

2019 EvidenceUpdates

6. Recurrent Uncomplicated Urinary Tract Infections in Women

Recurrent Uncomplicated Urinary Tract Infections in Women Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis (...) and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) Published 2019 [pdf] [pdf] Panel Members Jennifer Anger, MD, MPH; Una Lee, MD; A. Lenore Ackerman, MD, PhD; Roger Chou, MD; Bilal Chughtai, MD; J. Quentin Clemens, MD; Duane Hickling, MD, MSCI; Anil Kapoor, MD; Kimberly S. Kenton, MD, MS; Melissa R. Kaufman, MD, PhD; Mary Ann Rondanina, Ann

2019 American Urological Association

7. Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection

Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection SHTG Evidence Synthesis | 1 Evidence Synthesis Number 01 March 2019 Pre-emptive antifungal strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal strategies for invasive Aspergillus infection in patients with haematological malignancies What were we asked to look at? The Scottish Antimicrobial Prescribing Group (SAPG) asked us (...) to look at pre-emptive strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal treatment strategies for invasive Aspergillus infection in patients with haematological malignancies. Why is this important? Patients receiving treatments for haematological malignancies often experience severe and prolonged neutropenia which puts them at risk of life-threatening invasive fungal infections including Aspergillus infection. Since

2019 SHTG Advice Statements

8. Beta-D-glucan (BDG) tests for invasive Candida infection

Beta-D-glucan (BDG) tests for invasive Candida infection SHTG Advice Statement | 1 Advice Statement 02-19 January 2019 Advice Statement Clinical and cost effectiveness of diagnostic strategies incorporating Beta-D-glucan (BDG) tests to reduce unnecessary use of empirical antifungal therapies for invasive Candida infection in the critical care setting Advice for NHSScotland Overuse of empirical antifungal therapies in the critical care setting is a significant problem which exposes patients (...) is not fully offset by the savings realised from the reduction in antifungal use; SHTG Advice Statement | 2 ? The strategy is associated with a minimal incremental cost or is potentially cost- saving, in settings with higher testing throughputs (maximising test kit utilisation) and where there is low infection prevalence and high empirical use, and where micafungin or amphotericin B are the most commonly used agents; ? In units where use of empirical therapy is less common costs may be significantly

2019 SHTG Advice Statements

9. Curos for preventing infections when using needleless connectors

Curos for preventing infections when using needleless connectors Curos for pre Curos for prev venting infections when enting infections when using needleless connectors using needleless connectors Medical technologies guidance Published: 9 May 2019 www.nice.org.uk/guidance/mtg44 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived (...) . Curos for preventing infections when using needleless connectors (MTG44) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents Contents 1 Recommendations 4 2 The technology 6 3 Evidence 7 Clinical evidence 7 Cost evidence 8 4 Committee discussion 10 Clinical-effectiveness overview 10 NHS considerations overview 11 Cost modelling overview 12 Main cost drivers 12 Further research 12 5 Committee members

2019 National Institute for Health and Clinical Excellence - Medical technologies

10. The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)

The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, +31 January 2019] Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment C-REACTIVE PROTEIN POINT-OF-CARE (...) TESTING (CRP POCT) TO GUIDE ANTIBIOTIC PRESCRIBING IN PRIMARY CARE SETTINGS FOR ACUTE RESPIRATORY TRACT INFECTIONS (RTIS) Project ID: OTCA012 C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 26/10/2018 First draft. V1.1 03/12/2018 Input from co-author has been processed. V1.2 03/12/2018 Input from dedicated reviewers has been

2019 EUnetHTA

11. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection | The Ontario HIV Treatment Network The Ontario HIV Treatment Network A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

12. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. (PubMed)

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection.We conducted a trial involving transplantation (...) of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. The primary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival at 6

2019 NEJM

13. Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries. (PubMed)

Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries. The recommended management for neonates with a possible serious bacterial infection (PSBI) is hospitalisation and treatment with intravenous antibiotics, such as ampicillin plus gentamicin. However, hospitalisation is often not feasible for neonates in low- and middle-income countries (LMICs). Therefore, alternative options for the management of neonatal PSBI in LMICs

2019 Cochrane

14. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. (PubMed)

Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following

2019 JAMA

15. Surgical site infections: prevention and treatment

Surgical site infections: prevention and treatment Surgical site infections: pre Surgical site infections: prev vention and ention and treatment treatment NICE guideline Published: 11 April 2019 nice.org.uk/guidance/ng125 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Surgical site infections: prevention and treatment (NG125) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents Overview 4 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Synovasure Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection

Synovasure Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection Synovasure® Alpha Defensin Lateral Flow Test Kit - Health Technology Wales > Synovasure® Alpha Defensin Lateral Flow Test Kit Synovasure® Alpha Defensin Lateral Flow Test Kit Topic Status Incomplete Synovasure ® Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection. Summary Health Technology Wales researchers searched for evidence on whether the Synovasure (...) test can improve the diagnosis of periprosthetic joint infection. HTW’s Assessment Group concluded to progress this topic to Evidence Appraisal. The findings will be published as Evidence Appraisal Report EAR008. Please refer to this for the final agreed inclusion criteria for evidence. Topic Exploration Report TER015 (10.2018) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking

2019 Health Technology Wales

17. Tobramycin - treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis

Tobramycin - treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886328/2018 EMEA/H/C (...) /005086 Tobramycin PARI (tobramycin) An overview of Tobramycin PARI and why it is authorised in the EU What is Tobramycin PARI and what is it used for? Tobramycin PARI is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis. Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections. P. aeruginosa

2019 European Medicines Agency - EPARs

18. Urological Infections

Urological Infections Urological Infections | Uroweb › Urological Infections Urological Infections To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . G. Bonkat (Chair), R.R. Bartoletti, F. Bruyère, T. Cai, S.E. Geerlings, B. Köves, S. Schubert, F. Wagenlehner Guidelines Associates: T. Mezei, A. Pilatz, B. Pradere, R. Veeratterapillay TABLE OF CONTENTS REFERENCES 1. Radmayr, C., et al. EAU (...) by Jeremy Howick March 2009. 1998. 5. Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049. 6. Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309. 7. Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration

2019 European Association of Urology

19. Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1)

Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

20. Diagnosis and Prevention of Periprosthetic Joint Infections

Diagnosis and Prevention of Periprosthetic Joint Infections 1 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 DIAGNOSIS AND PREVENTION OF PERIPROSTHETIC JOINT INFECTIONS CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors March 11, 2019 Please cite this guideline as: American Academy of Orthopaedic Surgeons. Diagnosis and Prevention of Periprosthetic Joint Infections Clinical Practice (...) Diagnosis 7 Diagnosis of Infected Joint Replacements 8 Diagnostic Imaging 9 Gram Stain 9 Avoiding antimicrobials two weeks prior to obtaining intra-articular culture to identify a pathogen for the diagnosis of PJI 9 Avoiding Initiating Antimicrobials prior to Obtaining Intra-Articular culture in patients suspected of having PJI 10 Antibiotics with low preoperative suspicion of PJI or established PJI with a known pathogen 10 Perioperative Antibiotic Selection 10 Antibiotic Cement 11 Preoperative

2019 American Academy of Orthopaedic Surgeons